Palisade Asset Management LLC Has $5.76 Million Position in Danaher Co. (NYSE:DHR)

Palisade Asset Management LLC increased its position in Danaher Co. (NYSE:DHR) by 0.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,880 shares of the conglomerate’s stock after buying an additional 117 shares during the quarter. Palisade Asset Management LLC’s holdings in Danaher were worth $5,756,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Banco Santander S.A. acquired a new position in shares of Danaher in the third quarter valued at approximately $683,000. First Citizens Bank & Trust Co. increased its position in Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after purchasing an additional 149 shares during the period. Cercano Management LLC increased its position in Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after purchasing an additional 20,715 shares during the period. Allspring Global Investments Holdings LLC increased its position in Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after purchasing an additional 96,395 shares during the period. Finally, Parkside Financial Bank & Trust increased its position in Danaher by 4.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joakim Weidemanis sold 22,433 shares of the business’s stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $250.46, for a total value of $5,618,569.18. Following the completion of the sale, the executive vice president now owns 90,412 shares in the company, valued at $22,644,589.52. The disclosure for this sale can be found here. Insiders have sold 103,984 shares of company stock worth $25,997,094 in the last ninety days. Company insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Citigroup increased their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and increased their price target for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Raymond James increased their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. KeyCorp increased their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, Bank of America increased their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $267.31.

Danaher Stock Up 0.3 %

NYSE:DHR traded up $0.79 during trading hours on Wednesday, hitting $249.55. 1,443,446 shares of the company traded hands, compared to its average volume of 2,724,113. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The firm’s 50-day simple moving average is $248.27 and its 200-day simple moving average is $233.19. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company has a market cap of $184.84 billion, a PE ratio of 42.18, a PEG ratio of 3.82 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same period last year, the business earned $2.36 EPS. The business’s revenue was down 2.6% on a year-over-year basis. Equities analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s payout ratio is 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.